Ragazzi Eugenio, Costa Carlo V L, Comai Stefano, Bertazzo Antonella, Caparrotta Laura, Allegri Graziella
Department of Pharmacology and Anaesthesiology, University of Padova, Largo E. Meneghetti 2, I-35131 Padova, Italy.
Life Sci. 2006 Jan 18;78(8):785-94. doi: 10.1016/j.lfs.2005.05.077. Epub 2005 Aug 26.
Since alterations of tryptophan metabolism have been reported in diabetes and atherosclerosis, it was thought of interest to investigate any role of cloricromene through the influence on the oxidative metabolism of the amino acid by using diabetic/hyperlipidemic rabbits. Male 4-month-old New Zealand white rabbits, fed a diet enriched with 1% cholesterol and 10% corn oil, were made diabetic with alloxan. During the hyperlipidemic diet, a group of rabbits was treated with cloricromene (10 mg/kg/day subcutaneously plus 1.5 mg/kg/day intravenously, for 5 weeks). The other group received saline. Normometabolic New Zealand rabbits fed standard diet, treated or not with cloricromene, were used as control. The specific activities of liver tryptophan 2,3-dioxygenase and small intestine indole 2,3-dioxygenase were not significantly changed by the drug treatment. Also the specific activities of other enzymes of the kynurenine pathway in the liver and kidneys, specifically kynurenine 3-monooxygenase, kynureninase and kynurenine-oxoglutarate transaminase, did not show any significant difference in both tissues between the two groups of rabbits. On the contrary, 3-hydroxyanthranilate 3,4-dioxygenase activity in the liver of diabetic/hyperlipidemic rabbits and control rabbits treated with cloricromene showed a slight increase in comparison with untreated animals. Conversely, the specific activity of the enzyme in kidneys was not affected by the drug treatment in diabetic/hyperlipidemic animals but was reduced in controls. Aminocarboxymuconate-semialdehyde decarboxylase specific activity remained unchanged in the liver following cloricromene treatment, instead the specific activity of the enzyme in the kidneys of the diabetic/hyperlipidemic rabbits was significantly increased by the drug, with a value more than double in comparison to untreated animals. The activity of the scavenger enzyme Cu/Zn superoxide dismutase (Cu/Zn SOD) in the small intestine was also determined and found significantly increased of about twice as much in the group of diabetic/hyperlipidemic rabbits treated with cloricromene. In conclusion, in diabetic/hyperlipidemic rabbits, cloricromene appeared to influence the enzymes involved in the last steps of tryptophan oxidative metabolism through the kynurenine pathway. This, together with the antioxidant action through the activation of Cu/Zn SOD, might deserve further investigation for evaluating any link between the observed experimental findings at the level of the kynurenine pathway and the clinical effect of the drug.
由于在糖尿病和动脉粥样硬化中已报道色氨酸代谢存在改变,因此通过使用糖尿病/高脂血症兔子来研究氯克罗孟通过影响氨基酸的氧化代谢所起的任何作用被认为很有意义。4月龄雄性新西兰白兔,喂食富含1%胆固醇和10%玉米油的饲料,用四氧嘧啶诱导糖尿病。在高脂血症饮食期间,一组兔子用氯克罗孟治疗(皮下注射10mg/kg/天加静脉注射1.5mg/kg/天,共5周)。另一组接受生理盐水。喂食标准饲料、无论是否用氯克罗孟治疗的正常代谢新西兰兔用作对照。药物治疗后,肝脏色氨酸2,3-双加氧酶和小肠吲哚2,3-双加氧酶的比活性没有显著变化。肝脏和肾脏中犬尿氨酸途径的其他酶,特别是犬尿氨酸3-单加氧酶、犬尿氨酸酶和犬尿氨酸-氧代戊二酸转氨酶的比活性在两组兔子的两种组织中也没有显示出任何显著差异。相反,糖尿病/高脂血症兔子肝脏和用氯克罗孟治疗的对照兔子肝脏中的3-羟基邻氨基苯甲酸3,4-双加氧酶活性与未治疗动物相比略有增加。相反,糖尿病/高脂血症动物肾脏中该酶的比活性不受药物治疗影响,但在对照动物中降低。氯克罗孟治疗后肝脏中氨基羧基粘康酸半醛脱羧酶的比活性保持不变,相反,糖尿病/高脂血症兔子肾脏中该酶的比活性因药物而显著增加,与未治疗动物相比增加了一倍多。还测定了小肠中清除酶铜/锌超氧化物歧化酶(Cu/Zn SOD)的活性,发现在用氯克罗孟治疗的糖尿病/高脂血症兔子组中显著增加了约两倍。总之,在糖尿病/高脂血症兔子中,氯克罗孟似乎通过犬尿氨酸途径影响参与色氨酸氧化代谢最后步骤的酶。这与通过激活Cu/Zn SOD的抗氧化作用一起,可能值得进一步研究,以评估在犬尿氨酸途径水平观察到的实验结果与该药物临床效果之间的任何联系。